Abstract
Aims
Hypoglycemia in small children with type 1 diabetes is difficult to manage if nausea, vomit or food refusal occurs. If oral carbohydrate cannot be used, there is a hypothetical risk of severe hypoglycemia. The present article describes the effect on glucose of small doses of subcutaneous glucagon to revert hypoglycemia and prevent severe events in small children with type 1 diabetes using a continuous glucose monitoring.
Methods
We analyzed 4 episodes of impending or mild hypoglycemia in 3 children with type 1 diabetes who refused to eat carbohydrates. Using a standard U-100 insulin syringe, children received one “unit” (10 μg) of glucagon subcutaneously for every year of age up to 15 units (150 μg). If the blood glucose did not increase within 30 min, the initial dosage was repeated at that time. Instructions were given by phone from the physician. At the following visit data from continuous glucose monitoring devices, insulin pump and glucometer were downloaded and reviewed retrospectively from the physician.
Results
Blood glucose from continuous glucose monitoring after one and 2 h was 127 ± 80 mg/dl and 165 ± 78 mg/dl, respectively. After a glucagon injection, there was a single recurrence of hypoglycemia, requiring another shot. The glucagon was well tolerated, except for nausea, present before the injection. None of the children were taken to our hospital because of concerns for hypoglycemia.
Conclusion
Mini-doses of glucagon given subcutaneously were effective and safe in preventing frank or impending hypoglycemia in type 1 diabetes children refusing food.
Similar content being viewed by others
References
Abraham MB, Jones TW, Naranjo D et al (2018) ISPAD clinical practice consensus guidelines 2018: assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes 19(Suppl 27):178–192. https://doi.org/10.1111/pedi.12698
Karges B, Rosenbauer J, Holterhus PM et al (2015) Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes. Eur J Endocrinol Eur Fed Endocr Soc 173(3):341–350. https://doi.org/10.1530/EJE-15-0129
McCrimmon RJ, Gold AE, Deary IJ, Kelnar CJ, Frier BM (1995) Symptoms of hypoglycemia in children with IDDM. Diabetes Care 18(6):858–861
Bonaventura A, Montecucco F, Dallegri F (2015) Update on strategies limiting iatrogenic hypoglycemia. Endocr Connect 4(3):R37–R45. https://doi.org/10.1530/EC-15-0044
Barnard K, Thomas S, Royle P, Noyes K, Waugh N (2010) Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatrics 10:50. https://doi.org/10.1186/1471-2431-10-50
Boido A, Ceriani V, Pontiroli AE (2015) Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol 52(2):405–412. https://doi.org/10.1007/s00592-014-0665-0
Biester T, Kordonouri O, Holder M et al (2017) “Let the algorithm do the work”: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients. Diabetes Technol Therap. https://doi.org/10.1089/dia.2016.0349
Hartley M, Thomsett MJ, Cotterill AM (2006) Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 42(3):108–111. https://doi.org/10.1111/j.1440-1754.2006.00807.x
Haymond MW, Schreiner B (2001) Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 24(4):643–645
Chung ST, Haymond MW (2015) Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon. J Diabetes Sci Technol 9(1):44–51. https://doi.org/10.1177/1932296814547518
Haymond MW, DuBose SN, Rickels MR et al (2017) Efficacy and safety of mini-dose glucagon for treatment of non-severe hypoglycemia in adults with type 1 diabetes. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2017-00591
Rickels MR, DuBose SN, Toschi E et al (2018) Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care. https://doi.org/10.2337/dc18-0051
Ranjan A, Schmidt S, Madsbad S, Holst JJ, Norgaard K (2016) Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. Diabetes Obes Metab 18(4):410–418. https://doi.org/10.1111/dom.12627
Veronese G, Marchesini G, Forlani G et al (2016) Costs associated with emergency care and hospitalization for severe hypoglycemia. Nutr Metab Cardiovasc Dis NMCD 26(4):345–351. https://doi.org/10.1016/j.numecd.2016.01.007
Russell SJ, Hillard MA, Balliro C et al (2016) Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol 4(3):233–243. https://doi.org/10.1016/s2213-8587(15)00489-1
Wilson LM, Castle JR (2018) Stable liquid glucagon: beyond emergency hypoglycemia rescue. J Diabetes Sci Technol. https://doi.org/10.1177/1932296818757795
Sherr JL, Ruedy KJ, Foster NC et al (2016) Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care 39(4):555–562. https://doi.org/10.2337/dc15-1606
Acknowledgements
We would like to thank all participants and their families for sharing data with the scientific community.
Funding
The authors have no support or funding to report.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Human and animal rights
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Informed consent
Written informed consents were obtained from all patients for the publication of their reports. This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Additional information
Managed By Massimo Federici.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tinti, D., Rabbone, I. Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series. Acta Diabetol 57, 359–365 (2020). https://doi.org/10.1007/s00592-019-01443-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01443-1